Curtiss-Wright’s mission-critical defense and nuclear franchise is executing strongly, but a 47.6x P/E leaves valuation and multiple compression as the dominant investment risk.
Overview
Curtiss-Wright is a highly engineered, mission-critical supplier serving aerospace, defense, naval, commercial nuclear, process, and industrial markets. Its 9,200 employees support products that are difficult to replace because they require stringent certification, extreme-environment reliability, and lifetime customer support. **The core franchise is exceptionally durable:** approximately 70% of sales are aerospace and defense, the company holds sole- or single-source positions on important platforms, and backlog reached a record $4.5 billion with a 1.16x book-to-bill ratio. Q2 2026 sales rose 5.4% to $924.01 million, adjusted EPS rose 15% to $3.72, adjusted operating margin expanded 110 basis points to 19.4%, and free cash flow increased 37% to $160 million. Management raised 2026 sales guidance to $3.768-$3.813 billion and adjusted EPS guidance to $15.10-$15.40. Commercial nuclear expansion, defense modernization, and a $160 million 2026 buyback authorization are important catalysts. However, **valuation is the central constraint**: at $691.52, the stock trades at 47.6x trailing earnings versus a five-year median of 25.7x, while the DCF estimates $325.95 of intrinsic value.